New Zealand markets close in 1 hour 59 minutes

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
18.71+8.27 (+79.21%)
At close: 04:00PM EDT
18.66 -0.05 (-0.27%)
After hours: 07:58PM EDT
Full screen
Loading interactive chart…
  • Motley Fool

    Why Intercept Pharmaceuticals Stock Is Skyrocketing Today

    Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.

  • GlobeNewswire

    Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases

    Proposed all-cash acquisition will materially expand Alfasigma’s portfolio in gastroenterology and hepatology and its presence in the U.S. marketTransaction price represents an 82% premium to Intercept’s closing price on September 25, 2023Alfasigma adds Ocaliva®, the only FDA approved second-line treatment for PBC, a progressive autoimmune disease affecting the liver, which generated revenue of $152 million in 1H 2023Strengthens Alfasigma’s pipeline, including the addition of a novel fixed-dose

  • Motley Fool

    Why CymaBay Therapeutics Stock Is Jumping Today

    The continued momentum is a result of CymaBay's announcement yesterday of positive top-line results from a late-stage clinical study evaluating experimental drug seladelpar in treating primary biliary cholangitis (PBC), a rare chronic inflammatory liver disease. The great news for CymaBay, though, is that seladelpar appears to have a key advantage over those other PBC treatments. The results from the company's phase 3 study found that it significantly reduced itching, which is a major issue for many PBC patients.